Pure CBD was as potent or more potent than CBD oils at killing cancer cells, challenging the "entourage effect"

Pure CBD (10 μM) reduced cell viability in 3 of 6 cancer cell lines tested. None of the 3 commercial CBD oils reduced viability more than pure CBD. Dose-response curves showed lower IC50 values (higher potency) for pure CBD compared to the most potent oil. Some oils appeared to protect cancer cells from CBD effects. The anti-cancer activity was cell-line specific rather than cancer-type specific.

In vitro study testing pure CBD and 3 commercial CBD hemp oils (independently verified for CBD content and cannabinoid/terpene composition) against 6 human cancer cell lines from 3 cancer types using MTS viability assay and dose-response curves.

The "entourage effect" is frequently cited to argue that whole-plant cannabis products are superior to purified compounds. This study provides direct evidence against that claim for anti-cancer activity, finding pure CBD was equal or superior.

The finding that some CBD oils actually protected cancer cells is concerning. Other compounds in whole-plant extracts may interfere with CBD anti-cancer activity. This challenges assumptions about the superiority of full-spectrum products.

In vitro only (does not reflect in vivo tumor biology); limited to 6 cell lines; only tested one CBD concentration initially; commercial oils vary in composition; anti-cancer cell viability is not the same as treating cancer in patients.